coh ar 2006
Post on 05-Apr-2018
226 Views
Preview:
TRANSCRIPT
-
7/31/2019 COH AR 2006
1/54
c o l l a b o r a t i o n s 2006Annual Report
-
7/31/2019 COH AR 2006
2/54
1 Introduction
2 Leadership Message
4 Guarding Young Lives
8 Speeding Gene Therapies
12 Advancing Against Diabetes
16 Designing Smarter Drugs
20 Defeating Drug Resistance
24 Uniting Against Infection 28 Partners in Hope
32 Financials
38 Programs and Facilities
40 Research and Clinical Divisions, Departments and Programs
42 Administrative Leadership and Board of Directors
44 Faculty Leadership
50 Locations
-
7/31/2019 COH AR 2006
3/54
C i t y o f H o p e |
C o l l a b o r a t i o n s
Great discoveries and improvements invariably involve the
cooperation of many minds.alexander graham bell
Ct of Hope s an oranzaton stronl rooted n
enlhtened compasson. That compasson sexpressed not onl throh the care of patents,
bt also throh the dal qest for scentc
breakthrohs. For cancer patents here and
arond the world, tme s rretreabl precos.
Or crtcal oal to shorten the tme from ntal
scentc dea to new practcal treatment
nspres or researchers to work nselshl wth
scentc and medcal colleaes arond the
world. Ths shared son and collaboraton pas
off n dscoeres n basc scence, translatonal
research and, ltmatel, lfe-chann and lfe-
san medcal care.
-
7/31/2019 COH AR 2006
4/54
| C i t y o f H o p e
When we think o historys great scientists, we
oten imagine them toiling in solitude until a major
discovery thrusts them into the spotlight.
Modern-day biomedicine bears little
resemblance to that o the past. Today, scientic
researchers must join orces to speedily pursue cures
or disease.
So uickly has the worlds body o medical
knowledge grown that a scientist cannot expect
to know enough to unction alone. Each must
develop a niche o specialization an area where
the scientist reigns as an expert over a uniue and
complex domain; then, to aggressively advance
science, researchers must orm teams in which each
member has critical knowledge to oer. Only then
can ideas rom the lab move speedily rom cell
culture to the clinic.
Phlp L. Enel
Mchael A. Fredman, M.D.
-
7/31/2019 COH AR 2006
5/54
C i t y o f H o p e |
City o Hope symbolizes this collaborative
movement; and as City o Hope moves ahead with
its 2007-2013 strategic plan, collaborations take on
even greater importance. The strategic plan guides
the institutions expansion through key research,
clinical and education programs while maintaining
longstanding attributes, such as compassionate care,
that are central to its mission.
The strategic plan will help City o Hope
develop leading research programs in areas such as
cancer biology, experimental therapeutics and
population sciences, as well as strengthen clinical
areas o excellence, including leukemia and
lymphoma. It will build robust programs in areas
such as lung, gynecologic and musculoskeletal
cancers, among others. These aspirations are
impossible without collaboration.
The work o Smita Bhatia, M.D., M.P.H., chair
o the Division o Population Sciences, serves as just
one o several examples you will see in the ollowing
pages o this report. Bhatia studies childhood cancer
patients to deeply understand what happens later in
their lives, long ater cancer treatment. But studying
only City o Hopes patients would provide too
ew research subjects to statistically discern the
true eects o childhood cancer therapy. To ully
understand these long-term eects, Bhatia must pool
our patients with many others. She must link with
physicians and researchers across the world.
Only by combining their experiences and
unselshly sharing their data can Bhatia and her
colleagues gauge the long-term eects o cancer
treatment. As a result, the collaborating researchers
can better monitor cancer survivors health and
uality o lie and provide better guidance or
patients throughout their lives.
Just like Bhatia, other City o Hope
researchers are reaching beyond the bounds o
their oces and labs to cooperate with scientists
in Caliornia and around the globe. At the heart
o their mission: uncovering the science behind the
diseases and discovering better ways to prevent,
diagnose and treat cancer, diabetes, HIV/AIDS and
other serious illnesses.
We invite you to read about their stories, and
those o their collaborating City o Hope colleagues,
in this report.
Philip L. Engel
Chair, Board o Directors
City o Hope
Michael A. Friedman, M.D.
President and Chie Executive Ofcer
City o Hope
-
7/31/2019 COH AR 2006
6/54
| C i t y o f H o p e
Upper left:
Wend Lander, R.N., M.S.N.,
Ct of Hope
Center:
Ct of Hope patents, lke
the on rl shown here,
benet from the collaboraton
between cancer researchers
and clncal care proders.
Lower right:
Smta Bhata, M.D., M.P.H.,
Ct of Hope
-
7/31/2019 COH AR 2006
7/54
C i t y o f H o p e |
guARDiNgyOuNg LivESchildrens oncology group
The diagnosis o cancer in a child is overwhelming to amilies.
Even ater successul treatment, ears remain. Will it return?
Will a dierent cancer arise later in lie? What side eects can be
expected and can they be avoided?
Research has dramatically improved survival rates or children
with cancer, rom less than 25 percent in the 1960s to nearly
80 percent today. More than 250,000 childhood cancer survivors are
living in the United States alone. But as they mature, two-thirds will
suer chronic problems and long-term complications, such as issues
related to growth and development; one-third will have a problem
that can be lie threatening. Many will develop secondary cancers,
either due to cancer treatment or underlying causes.
Because late eects may not arise until decades ater
treatment, and because pediatric cancers are ortunately rare,
researchers and care providers must pool their resources and share
their experiences to improve long-term outcomes. City o Hope
researchers are national leaders in this eort.
Smita Bhatia, M.D., M.P.H., chair o the Division o Population
Sciences at City o Hope, and medical director, Center or Cancer
Survivorship, chairs the Late
Eects Committee o the Childrens
Oncology Group (COG), a
consortium unded by the National
Cancer Institute.
-
7/31/2019 COH AR 2006
8/54
| C i t y o f H o p e
COG brings together pediatric cancer experts
rom 238 hospitals in the U.S., Canada, Australia,
New Zealand, the Netherlands and Switzerland. It
acilitates the organization o large-scale, denitive
multicenter research studies needed to improve
treatments, practices and outcomes. Today, more
than 90 percent o children with cancer in the U.S.
are treated at COG-aliated cancer centers, and
about 70 percent participate in clinical trials.
Bhatia serves as principal investigator or
a COG research study looking at key adverseevents in childhood cancer survivors. Patients who
develop a secondary cancer or other problem such
as congestive heart ailure or stroke are invited to
participate in the study so that the causes o these
complications can be investigated, potentially
improving uture treatments.
At City o Hope, cancer research is strongly
integrated with clinical care, and nursing is a central
ocus o that strategy. Wendy Landier, R.N., M.S.N.,
serves as clinical director o the Center or Cancer
Survivorship, and also leads the Nursing Clinical
Practice/Survivorship Subcommittee o COG, where
she serves as vice chair o the Nursing Discipline. As
leaders within both City o Hope and COG, Landier
and Bhatia have collaborated on landmark projects
including the establishment o long-term ollow-up
guidelines or young cancer survivors and a resource
guide or all COG centers to use in their own
ollow-up programs.
Participation in COG encourages alliances.
Close ties have been established with researchers
at St. Jude Childrens Research Hospital, The
Childrens Hospital o Philadelphia, Memorial
Sloan-Kettering Cancer Center and dozens o
other institutions. A Web-based version o the
long-term ollow-up guidelines that can be tailored
or individual patients will soon be launched inpartnership with Baylor School o Medicine. As a
pilot test center or the new system, City o Hope
and its patients will benet rom instant access
to the cumulative knowledge o pediatric cancer
experts rom around the world.
Toda, more than 90 percent
of chldren wth cancer n the
unted States are treated at
Chldrens Oncolo grop-
aflated cancer centers.
-
7/31/2019 COH AR 2006
9/54
C i t y o f H o p e |
Ct of Hope pedatrc patents
benet from the collaborate
efforts of researchers at
Ct of Hope and dozens of other
nstttons worldwde.
-
7/31/2019 COH AR 2006
10/54
| C i t y o f H o p e
SPEEDiNggENE
THERAPiESnational gene vector laboratoryThe most powerul weapons against cancer, diabetes and other
serious diseases cannot be seen. They are genes bits o DNA that
can be delivered to wayward cells, xing problems at the source.
Gene therapy holds huge potential or uture cures. But rening these
genetic tools, manuacturing them in uantity and getting them into
clinical trials is a major challenge on all ronts: technical, analytical
and regulatory.
The National Gene Vector Laboratory (NGVL) at City o Hope
is helping make it happen. Located within the Center or Biomedicine
& Genetics (CBG), the NGVL is the rst large-scale acility or
manuacturing biological therapeutics at an academic research center
in the United States. Here, promising new genetic and cellular agents
created by researchers can move into production rapidly, so that they
can be entered into clinical trials without delay.
The two-story, 20,000-suare-oot CBG acility was built
in 2000 with the purpose o creating an unlimited array o novel
therapeutics. Led by Larry A. Couture, Ph.D., the CBG currently
produces islet cells that treat type 1 diabetes, monoclonal antibodies
that ght cancer, engineered T-cells or immunotherapeutic clinical
trials, cancer vaccines, viral vectors or gene therapy against HIV,
and hematopoietic cell products
to treat blood disorders. Process
development is also beginning on
two types o recombinant proteins,
similar to the way City o Hope
achieved a breakthrough in the
development o synthetic human
insulin nearly 20 years ago.
-
7/31/2019 COH AR 2006
11/54
C i t y o f H o p e |
Lower left:
Larr A. Cotre, Ph.D., Ct of Hope
Center:
Ct of Hope manfactres
nestatonal noel therapetcs for
researchers arond the contr.
Upper Right:
Mchael C. Jensen, M.D. ,
Assocate Char,
Dson of Cancer immnotherapetcs
and Tmor immnolo, Ct of Hope
-
7/31/2019 COH AR 2006
12/54
0 | C i t y o f H o p e
Ct of Hopes Natonal gene vector
Laborator rapdl manfactres
bolocal therapetcs so that thesenew therapes can moe nto clncal
trals wthot dela.
1997
1998
2000
1999CBg conceed
Ma 1998
CBg fnded
Jl 1998
Bean constrcton
of CBg
Janar 1999 CBg completed
Febrar 2000
-
7/31/2019 COH AR 2006
13/54
C i t y o f H o p e |
produced a lentivirus vector and is a designated
back-up site or the production o adenovirus gene
therapy vectors.
With its robust manuacturing capacity and
ability to uickly produce novel therapeutics at
a small scale, the CBG provides a ast track or
scientists seeking to move their research rom bench
to bedside. It also generates valuable collabora-
tions between City o Hope and other institutions.
With material rom the NGVL, Jennier Grandics,
M.D., at the University o Pittsburgh has made rapid
progress in antisense gene therapy that can inhibit
cancer o the head and neck. At the Universityo Wisconsin, Douglas McNeel, M.D., Ph.D., is
taking a promising DNA plasmid vaccine that ghts
prostate cancer into phase II clinical trials. In the
search or better, aster cures, City o Hope is giving
researchers across the country the genetic tools they
need today.
The CBGs prolic output, scientic expertise
and certication as a Good Manuacturing Practices
acility led the National Institutes o Health (NIH)
to commission it as an NGVL, one o only ve
such acilities in the U.S. today. Specically, the
laboratory produces clinical-grade DNA plasmid
vectors or use in phase I and II clinical protocols.
DNA plasmids, also called naked DNA, are
circular pieces o DNA carrying genes that can be
transerred into cells with therapeutic eects.
Plasmids are in demand by researchers because
unlike viral vectors, they have the advantage o
producing little or no immune response. As the
only NIH-supported plasmid manuacturer in
the U.S., City o Hopes NGVL produces DNA
plasmids or all ualied, ederally unded labora-tories nationwide. In addition, the acility also has
Ct of Hope prodces
DNA plasmds for all
qaled, federall fnded
laboratores natonwde.
Desnated Sothern Calforna
islet Cell Resorce Center
September 2001
2001
2002
Frst prodcton
December 2000
Desnated
Natonal gene vector Lab
September 2001
Calforna
Food and Dr
Branch Lcense
March 2002
CbG ManUFaCtUrED ProDUCts
MANuFACTuRE PRODuCT PRODuCTDATE NAME TyPE
12/12/2001 iL-13 Plasmd DNA
1/14/2002 CE7R Plasmd DNA
7/22/2002 293 Hman Cell MCB
8/22/2002 293T Hman Cell MCB
4/17/2003 TM-LCL Hman Cell MCB
4/30/2003 L29.19 Plasmd DNA
5/23/2003 pTvg-hPAP Plasmd DNA
1/29/2004 EgFRAS Plasmd DNA
2/25/2004 T84.66 Dabod Monoclonal Antbod
6/14/2004 Ant-CD19 Plasmd DNA
1/3/2005 pHiv7-sh-TAR- Plasmd DNACCR5RZ
1/12/2005 TM-LCL Hman Cell WCB
1/20/2005 pCp Plasmd DNA
3/21/2005 pCMv-Re2 Plasmd DNA
5/12/2005 pCMv-g Plasmd DNA
6/1/2005 Lentrs vral vector6/20/2005 pHiv7-sh-TAR- Plasmd DNA
CCR5RZ
12/14/2005 gene Moded Enneered patent-specc cellsT-cell
2/15/2006 Ant-CEA hT84.66 Monoclonal AntbodM5A/NHS-DOTA
3/23/2006 pCB-AT-Zero Plasmd DNA
4/25/2006 Zenapax Monoclonal Antbod
5/2006 Lentrs vral vector
6/2006 pCMv-Re2 Plasmd DNA
8/2006 gene Moded Enneered patent-specc cellsT-cell
12/2006 CD19Rop epHiv7 Plasmd DNA
-
7/31/2019 COH AR 2006
14/54
| C i t y o f H o p e
Upper left:
Foad R. Kandeel, M.D., Ph.D.,
Ct of Hope
Center:
genomc analss of slet
fncton.
Lower right:
Donald C. Dafoe, M.D.,
Drector, Pancreas Transplanton,
Cedars-Sna Medcal Center
-
7/31/2019 COH AR 2006
15/54
C i t y o f H o p e |
ADvANCiNgAgAiNST
DiABETESislet cell transplantationThe greatest challenge in medical research is to nd a permanent cure
or a lie-threatening disease. For 5 million people around the world,
that disease is type 1 diabetes.
Also called insulin-dependent diabetes, type 1 diabetes is an
autoimmune reaction that destroys the beta cells o the pancreas.
The result is a lietime o insulin injections, threats o cardiovas-
cular, nerve and kidney disease, and dangerous low-blood-sugar
episodes. While healthy insulin-producing pancreatic islet cells can
be transplanted rom donor organs, donors are in short supply.
And transplant procedures reuire special technology, immune-
suppressing drugs and considerable expertise.
City o Hope is a leader in diabetes research, having pioneered
the development o Humulin, the synthetic human insulin that was
the rst biotechnology product approved by the Food and Drug
Administration, now used by millions o diabetics worldwide.
That leadership continues with advancing islet cell transplantation.
As one o only seven islet cell resource
(ICR) centers unded by the National
Institutes o Health, City o Hope
perormed the most islet transplants in the
United States in 2004 and 2005 and has
distributed the largest number o islets to
basic science programs in the U.S. since
2004. City o Hope is the only currently
unded ICR center in the western U.S.
In 2006, the Juvenile Diabetes Research
Foundation (JDRF) designated City o Hope
Cy f Hpe ewed
dee pgm, cudg
fevg wk e ce
p, cezed
he lee d su Gd(Gdchmed) Dee d
Geec reech Cee
Cy f Hpe.
-
7/31/2019 COH AR 2006
16/54
| C i t y o f H o p e
1940
1950
1970
1960Rachmel Lene, M.D., Ct of Hope,
dscoers pathophsolocal bass
of tpe 2 dabetes n 1949
as a JDRF Islet Cell Transplant Center, making it
one o only 14 in the nation and the only Southern
Caliornia organization to receive this distinction.
Three clinical trials involving islet cell
transplantation are under way at the City o Hope
Leslie and Susan Gonda (Goldschmied) Diabetes
and Genetic Research Center led by Fouad R.
Kandeel, M.D., Ph.D, director, Department o
Diabetes, Endocrinology & Metabolism. One study
seeks to improve upon the Edmonton Protocol, a
widely adopted transplant procedure reuiring two
to three islet cell inusions. Multiple inusions and
organ donors are needed because the drugs used toovercome transplant rejection are toxic to islet cells.
As an alternative, the City o Hope phase I/II trial is
employing a dierent immune suppression strategy
together with the use o growth actors to expand
the number o islet cells beore and ater transplan-
tation. The goal is to develop a single inusion that
can ree patients rom insulin dependence.
Kandeel also directs the Southern Caliornia
Islet Consortium (SC-IC), a group o institutions
sharing resources and expertise. Hosted by
City o Hope, the SC-IC includes Cedars-Sinai
Medical Center, Harbor-UCLA Medical Center,
Loma Linda Medical Center, the Southern Caliornia
Transplantation Institute, St. Vincent Medical Center,
the Whittier Institute or Diabetes/Scripps Green
Center or Organ & Cell Transplantation and the
UCLA Center or Health Sciences. Because kidney
disease is a complication o diabetes, the SC-ICs
rst multicenter clinical trial ocuses on islet cell
transplantation ater kidney transplant. City o Hope
perorms the majority o transplant procedures or
the consortium, handles regulatory reuirements
and trains physicians in islet cell techniues.
With diabetes on the rise worldwide, the
absolute shortage o islet cell donors is stimulating
the search or new islet cell strategies, including
stem cells. Looking beyond diabetes, progress
in immune tolerance achieved through islet cell
research could pave the way or advances in solid
organ transplants, cellular and gene therapies and
treatments or autoimmune conditions, Parkinsonsdisease and many other conditions that would
benet rom cell replacement.
Ct of Hope hosts the Sothern
Calforna islet Consortm,whch represents an nterated
effort of mltple academc and
transplant nstttons to mere
resorces and efforts n slet
transplantaton research.
Samal Rahbar, M.D., Ph.D.,
Ct of Hope, dscoers
HA1c n 1968
-
7/31/2019 COH AR 2006
17/54
C i t y o f H o p e |
yoko Fjta-yamach, Ph.D.,
Ct of Hope, dscoers cell nsln
receptor n 1982
1980
1990
2000
2010
Ct of Hope researchers work on
slet cell solaton and dstrbton
for clncal transplantaton trals
throhot the unted States.
Arthr Rs, Ph.D., and Kech itakra, Ph.D., both
from Ct of Hope, prodce snthetc nsln from
enetcall enneered bactera n1978
Establshment of the Sothern
Calforna islet Cell Resorce
Center n 2001 Stem cell transplantaton w
mmne sppresson for trea
of dabetes n the
Ct of Hope desnated as a Jenle Dabetes Research
Fondaton islet Cell Transplant Center n 2006
Lesle and Ssan gonda
(goldschmed) Dabetes and
genetc Research Center
dedcaton n 1997
-
7/31/2019 COH AR 2006
18/54
| C i t y o f H o p e
DESigNiNgSMARTER
DRugSmodeling g-protein coupled receptorsMany drugs in use today were created by trial and error methods
that result in a compromise: The drugs work, but carry risks o
unwanted side eects. Yet clues to designing smarter pharmaceu-
ticals with ewer side eects are hidden within the three-dimensional
structures o biomolecules that these drugs turn on or o.
Among the most important therapeutic drug targets in the
human body are G-protein coupled receptors (GPCRs) a large,
diverse group o proteins that play crucial roles in health and disease.
Woven through cell membranes, GPCRs act as signal posts, sensing
changes in the environment and directing the cell to respond. By
binding with neurotransmitters, hormones, immune substances,
odorants and other molecules, GPCRs infuence growth, metabolism,
brain response and other central lie processes. GPCRs called
chemokine receptors are also implicated in the spread and growth o
many cancers, including those o the lung, breast, prostate and colon.
With rising rates o age-related and environmental cancers, better-
targeted magic bullet GPCR drugs would have widespread benets.
In act, hal the drugs in use
today target GPCRs, activating
or inhibiting them. They are used
to lower blood pressure, combat
allergies, treat depression, calm
arthritis, heal stomach ulcers and
block pain. Yet their actions are oten
too broad, leading to side eects that
can be serious, even dangerous.
-
7/31/2019 COH AR 2006
19/54
C i t y o f H o p e |
Upper right:
Naarajan vadeh, Ph.D.,
Ct of Hope
Center:
3-D compter models of
protens help researchers
more qckl nestate
Wnt snal transdcton
pathwas noled n
deelopment and dsease.
Lower left:
Randall T. Moon, Ph.D.,
unerst of Washnton
P
hotobyElzabethLowry,2006
u
nverstyofWashngtonMedcne
-
7/31/2019 COH AR 2006
20/54
| C i t y o f H o p e
Teams of chemsts, phscsts and
compter scentsts work to prodce
rtal gPCR models, then aldate and
rene them to ltmatel brn mch-
needed gPCR drs to patents.
-
7/31/2019 COH AR 2006
21/54
C i t y o f H o p e |
o computers. Then, urther experiments are needed
to validate and rene the model.
But while the structures may be theoretical,
the need or progress in GPCR drugs is real.
Interest in GPCR structures is attracting pharma-
ceutical companies to work with City o Hope, and
promotes collaborations with the universities o
Caliornia, Texas, Pittsburgh and North Carolina,
Caliornia Institute o Technology, Jet Propulsion
Laboratory, New York University and Imperial
College London, among others.
At the University o Washington, scientistRandall T. Moon, Ph.D., had evidence that a
certain GPCR was involved in cancer, but needed
to understand its structure, as well as identiy
small molecules that could turn the receptor on
or o. Working together with Moon, Vaidehis
team predicted the receptors structure and rapidly
identied 20 possible modulators rom a database o
hundreds o thousands o molecules one o which
may be a perect t.
Designing the next generation o GPCR drugs
reuires data on the three-dimensional structure
o each receptor protein. But because membrane-
bound proteins are hard to crystallize, their
structures cannot be visualized directly. One solution
is to construct virtual models o these receptor
proteins using computational methods based on the
undamental laws o physics. It is a challenge that
takes teams o chemists, physicists and computer
scientists to solve.
At City o Hopes Division o Immunology,
Nagarajan Vaidehi, Ph.D., is leading the charge.
Starting with basic atomic orces, she and her
colleagues predict the theoretical 3-D structures and
binding sites o small molecules within GPCRs. Each
structure reuires months to generate, using dozens
interest n proten strctress attractn pharmacetcal
companes and nerstes
across the lobe to work wth
Ct of Hope.
-
7/31/2019 COH AR 2006
22/54
0 | C i t y o f H o p e
Upper left:
Mark E. Das, Ph.D.,
Warren and Katharne Schlner
Professor of Chemcal Enneern,
Calforna insttte of Technolo
Center:
Hman dose al of rboncleotde
redctase nhbtor sed n the rst
clncal tral.
Lower right:
yn yen, M.D., Ph.D., Ct of Hope
PhotocortesyofCalfornainsttteofTechnology
-
7/31/2019 COH AR 2006
23/54
C i t y o f H o p e |
DEFEATiNgDRug
RESiSTANCEribonucleotide reductase inhibitorsMany cancer drugs seem to work well at rst. But too oten, the
disease returns. And when it does, it can hit even harder and aster
than beore. Many cancers actually develop resistance to chemo-
therapy. Finding a way to deeat this drug resistance is a signicant
step toward nding a cure.
At City o Hope, Yun Yen, M.D., Ph.D., director o Clinical
and Molecular Pharmacology and co-leader o the Developmental
Cancer Therapeutics Program, believes the answer may be ound in
an enzyme that cells use naturally to repair and restore themselves.
The enzyme ribonucleotide reductase (RR) converts ribonucleotides
into the building blocks o DNA, an essential part o the normal
process o cell growth, including the ability to x damaged genes.
But in cancer cells, RR production can go into overdrive, allowing
cancers to survive attacks by chemotherapy and promoting the
spread o new malignant cells that can invade healthy tissues.
For 17 years, Yens research has ocused on understanding
the gene that codes or RR and how the enzyme itsel helps cancer
spread. One well-known chemotherapy drug, hydroxyurea, is
known to work by inhibiting RR. But i surviving cancer cells learn
to resist the drug, it can lead to recurrence. Today, Yens group is
pressing to nd more eective
anticancer agents, including
combining newer RR inhibitors
with gemcitabine, the only drug
approved or pancreatic cancer.
-
7/31/2019 COH AR 2006
24/54
| C i t y o f H o p e
2004
2005Branstormn sesson wth Mark E. Das, Ph.D.,
CalTech, and yn yen, M.D., Ph.D., and
Stephen J. Forman, M.D., both from Ct of Hope
Yen discovered the mechanism by which cancer
cells become resistant to gemcitabine a nding
that is actively being exploited in the search or new
cancer drugs.
Collaborative research is accelerating progress
in overcoming drug resistance. Within City o Hope,
David Horne, Ph.D., director o the Synthetic
Chemistry Core Facility, and Yate-Ching Yuan, Ph.D.,
manager o the Biomedical Inormatics Core Facility,
are designing new compounds with the ability to
inhibit RR. These are tested at City o Hopes High
Throughput Screening Core, directed by M.L.Richard Yip, Ph.D. The core acility is a resource
where newly synthesized chemicals and thousands
more rom a library o molecules can be screened
rapidly to assess whether they hold potential as
possible treatments.
Meanwhile, Yen is also working with John
Rossi, Ph.D., Lidow Family Research Chair in the
Division o Molecular Biology, to investigate the
use o small interering RNA (siRNA) to silence
the genes that produce RR through a mechanism
called RNA intererence (RNAi). Rossi is using the
RNAi approach to ght HIV, and this approach
is one o the most promising new investigational
therapies or many diseases. The 2006 Nobel Prize
in Medicine was awarded or the discovery o the
RNAi mechanism.
Taking the siRNA strategy a step urther to
a level reminiscent o science ction City o Hope
researchers are pursuing an inter-institutional project
with Mark E. Davis, Ph.D., Warren and Katharine
Schlinger Proessor o Chemical Engineering at the
Caliornia Institute o Technology, and a local start-
up company called Calando Pharmaceuticals. Davis
has engineered nanoparticles made o polymers that
can deliver drugs directly to cancer cells.
Preclinical studies conducted by Calando
Pharmaceuticals suggested that nanoparticles
containing siRNA to inhibit RR can serve as sae,
eective drug-delivery vehicles. Plans or a clinicaltrial with cancer patients are already under way.
Scentsts at Ct of Hopeand Caltech are collaboratn
to deelop nanopartcles that
can deler drs drectl to
cancer cells.
Anmal std
Jne 2005
-
7/31/2019 COH AR 2006
25/54
C i t y o f H o p e |
FDA approal
en for clncal tral
March 2006
2006
2007
Ct of Hope researchers prse
ntra- and nter-nstttonal
projects to nd more effecte
antcancer aents.
Preclncal std
December 2005
Frst patent enrolled
nto clncal tral
Jl 2006 Three-dose-leel testn
December 2006
Abstract sbmtted at Amercan Socet
of Clncal Oncolo annal meetn
Janar 2007
-
7/31/2019 COH AR 2006
26/54
| C i t y o f H o p e
uNiTiNgAgAiNST
iNFECTiONcytomegalovirus vaccineStem cell and organ transplants oer hope to patients with cancer
and other serious illnesses. But or the transplant to succeed, the
patients own immune system must be suppressed to reduce the
chance o transplant rejection. And that opens the door to inection.
Too oten, patients whose immune systems have been weakened
all victim to cytomegalovirus (CMV), a common herpes virus that
can be ound in 50 to 80 percent o adults in the United States.
Normally, inections are mild; aterward, the virus remains dormant,
held in check by a healthy immune system. But ater a transplant or
other immune-compromising event, CMV can reactivate, causing
pneumonia and other deadly diseases. About hal o bone marrow
transplant patients develop active CMV inections; the virus also is a
major cause o death in organ transplant patients.
The list goes on: CMV harms dialysis patients, causes blindness
in HIV patients and is the leading congenital inection in newborns.
CMV is responsible or hundreds o inant deaths and thousands o
serious birth deects in babies annually. The Institute o Medicine has
called the development o a CMV vaccine a national medical priority.
While antiviral drugs can be eective
against CMV, they are undesirably toxic.
As a much-needed alternative, City o Hope
scientists have teamed up to develop a CMV
vaccine, based on years o accumulated
research. Their eorts took a giant leap
orward in 2006, when the Food and Drug
Administration approved the rst human
clinical trial o a synthetic CMV vaccine.
-
7/31/2019 COH AR 2006
27/54
C i t y o f H o p e |
Upper right:
Don J. Damond, Ph.D.,
Ct of Hope
Center:
Ctomealors and
red blood cell.
Lower left:
John A. Zaa, M.D.,
Ct of Hope
-
7/31/2019 COH AR 2006
28/54
| C i t y o f H o p e
Scentsts and phscans work toether
on a phase i clncal tral to ather
data on safet, metabolsm and other
parameters of the CMv accne.
-
7/31/2019 COH AR 2006
29/54
C i t y o f H o p e |
M.D., chair o the Division o Virology, and
Stephen J. Forman, M.D., Francis and Kathleen
McNamara Distinguished Chair in Hematology
and Hematopoietic Cell Transplantation. Coley
Pharmaceutical Group is contributing the adjuvant.
SAIC-Frederick and the NCI sponsored the
development o early data, and the Pasteur Institute
urnished preclinical models used in establishing
the potency o the vaccine.
In the next phase, transplant donors will
receive the vaccine to evaluate whether immunity
to CMV can be transerred along with their bonemarrow or other tissues. Meanwhile, Diamond and
his colleagues are pressing ahead with a second-
generation vaccine engineered by Zhongde Wang,
Ph.D., M.D., assistant research scientist in the
Division o Virology, to combat congenital CMV,
with broader applicability in transplant recipients;
the project has received long-term unding rom
the NCI. The National Institute o Allergy and
Inectious Diseases and Bernard Moss, M.D., Ph.D.,
chie in the Laboratory o Viral Diseases, have
provided a crucial component to this project, which
is anticipated to assist in regulatory approval.
Don J. Diamond, Ph.D., director o the
Laboratory o Vaccine Research, is heading a
project in which two ormulations o the vaccine are
being tested, each with and without a biochemical
regulator called an adjuvant. At the heart o the
vaccine is a peptide molecule that originated at
City o Hope and is now being produced or urther
studies by the National Cancer Institute (NCI).
In the phase I clinical trial, currently under
way, healthy adult volunteers are being given
the vaccine in one o its orms to gather data on
saety, metabolism and other parameters. Parties
collaborating in this groundbreaking project include
Corinna La Rosa, Ph.D., assistant research scientist,
and Simon F. Lacey, Ph.D., associate researchscientist in the Division o Virology, John A. Zaia,
At the heart of the accne
s a peptde molecle that
ornated at Ct of Hope and
s now ben prodced for
frther stdes b the Natonal
Cancer insttte.
-
7/31/2019 COH AR 2006
30/54
| C i t y o f H o p e
-
7/31/2019 COH AR 2006
31/54
C i t y o f H o p e |
PARTNERS iN HOPE
A landmark number o endowed chairs, beuests, generous gits
and grants in 2006 accelerated City o Hopes uest to develop
treatments and cures or those suering rom devastating diseases.
The generous giving refected the ongoing condence o supporters in
the organizations mission.
The year was one o unprecedented generosity. City o Hope
supporters gave more than $122 million, the most ever raised in a
single year. Beuests, or donations made through wills and trusts, also
surpassed previous levels, totaling nearly $34 million. The dedicated
eorts o thousands o individuals, oundations, corporations andvolunteer groups and auxiliaries nationwide contributed to this
remarkable year, ensuring that key City o Hope research, education
and treatment programs continue to grow and progress.
Furthering a partnership that began nearly a uarter century
ago, a $20 million git rom the Arnold and Mabel Beckman
Foundation established the Arnold and Mabel Beckman Center or
Cancer Immunotherapeutics and Tumor Immunology. This modern,
108,000-suare-oot acility will blend basic science with clinical
studies and ocus on immunotherapy, a treatment that uses the
immune system to ght cancer and other diseases.
In making their git, Arnold and Mabel Beckman Foundation
leaders pledged $15 million to match a $15 million git made by an
anonymous donor, and another $5 million to spur additional gits.
Other signicant support or the acility in 2006 included a
$2 million beuest rom the estate o Diana Chudaco Levin.
The project also received a commitment rom the National
Oce Products Council, the executive advisory board o the
National Oce Products Industry, which pledged $5 million rom
the industry groups annual undraising campaigns through 2009
to support the Arnold and Mabel Beckman Center. Conseuently,
$500,000 o the industry groups 2006 contributions was
earmarked or the National Oce Products Industry Cellular and
Tumor Immunotherapies Center, which will be located on the third
foor o the Arnold and Mabel Beckman Center.
The Arnold and Mabel Beckman Center also will house
City o Hopes Center or Graduate and Proessional Studies,
which beneted rom a $750,000 grant to establish and euip the
Ralph M. Parsons Foundation Teaching Laboratory.
Other important oundation support during the year included a
$511,130 grant rom The UniHealth Foundation to enhance nursing
training, a $500,000 grant rom the Skirball Foundation to support
Me d ad beckm
-
7/31/2019 COH AR 2006
32/54
0 | C i t y o f H o p e
T-cell therapy research or lymphoblastic leukemia, a $500,000
grant rom The Henry L. Guenther Foundation to purchase a 3T
magnetic resonance imaging machine, and $450,000 rom the W.M.
Keck Foundation to und research to understand the molecular
mechanisms underlying cancer and develop new therapies that would
destroy lymphoma cells without harming normal cells.
Another critical program, transusion medicine, beneted rom
the altruism o longtime Home Furnishings Industry group supporter
Michael Amini, chairman and chie executive ocer o Amini
Innovation Corporation, who contributed a $6 million git. The three-story Michael Amini Transusion Medicine Center will consolidate
City o Hopes blood collection and processing programs and provide
a modern, comortable environment or patients, donors and sta.
The unding o several new endowed chairs throughout the
year bolstered research eorts, as well. An unexpected beuest o
more than $5.8 million rom a Laguna Beach, Cali., couple whose
amily member was treated at City o Hope in the 1960s established
the Edward and Estelle Alexander Chair in Inormation Sciences.
As the rst holder o the new chair, City o Hope Cancer Center
Associate Director Joyce C. Niland, Ph.D., will continue leading
City o Hopes collaborations with other cancer centers to create a
global inormation model to speed uture biomedical research.
Stephen J. Forman, M.D., was named as the rst holder o the
Francis and Kathleen McNamara Distinguished Chair in Hematology
and Hematopoietic Cell Transplantation, established by a $2.5 million
git rom Kathleen McNamara, a patient o Formans, and her
husband, Francis Chip McNamara.
Another $2.5 million git rom the amily o late City o Hope
patient and prominent Las Vegas builder Martin Collins established
the Pauline and Martin Collins Family Chair in Urology. The rst
holder is Timothy Wilson, M.D., director o the Department o
Urology & Urologic Oncology and the Prostate Cancer Program.
Furthering years o commitment to City o Hope, Sheri
Biller, vice chair o the board o directors at City o Hope, and her
husband, Les, were inspired to enhance the institutions patient
support services. Aiming to create a single place where patients and
amilies can turn or help in coping with cancer, the Sheri & Les
Biller Family Foundation pledged $2 million to establish the Sheri &
Les Biller Patient and Family Resource Center.
Continuing their steadast support, more than 30 industry
groups generated tens o millions o dollars through undraising
Mche am
-
7/31/2019 COH AR 2006
33/54
C i t y o f H o p e |
endeavors such as Spirit o Lie galas and gol tournaments. The
Home Furnishings Industry raised a record $10 million, including
the $6 million Amini git, during their annual undraising eort.
The National Oce Products Industrys Give. Hope. campaign
yielded more than $6.2 million, while the Hardware/Homebuilding
Industry raised more than $3 million. Members o the ood and drug
industries groups in the western United States and Arizona raised
more than $4.8 million. And, urthering more than three decades o
support, the Music and Entertainment Industry generated more than
$3 million through its annual campaign.Additional entertainment industry support came through
promotional spots recorded by nine-time Grammy-winner and breast
cancer survivor Sheryl Crow. The spots began running nationwide
in all 2006 through airtime donated by Premiere Radio Networks
and Movie Tunes, raising City o Hopes prole across the country.
The ads reached more than 190 million radio listeners and played in
16,500 movie theaters in the United States.
Through alliances with national brands including 3M,
Hansens, Kelloggs, Oce Depot, OceMax, Mattel, Sanord and
Unilever, cause-related marketing programs raised a total o nearly
$4 million or City o Hope. Staples, one o the organizations largest
cause-marketing participants in 2006, created customer-donated
programs that garnered nearly $1 million and generated invaluable
national visibility or City o Hope.
Epitomizing the commitment o City o Hopes thousands
o auxiliary members nationwide, decades-long supporter Morris
(Morrie) Darnov and his daughter, Sharon, generously donated a
combined git o$2 million in memory o Natalie Darnov, Morries
wie and Sharons mother. For more than our decades, Natalie and
Morrie Darnov served as dedicated members o Los Angeles Git o
Lie Chapter. Morrie remains an active chapter member.
More than 22,000 participants in nine cities around the
nation raised more than $2.5 million in an eort to eradicate the
most prevalent cancer in women through City o Hopes national
campaign, Walk or Hope to Cure Breast Cancer. Increased
team participation and support rom national sponsors such as
Wells Fargo, 3M Post-It Sticky Notes, Hilton HHonors, Good
Housekeepingmagazine, Orbitz and Sandals/Beaches resorts, as
well as cash sponsors Bamboo, Anne Michelle and Sebastian Body
Double, all contributed to a successul Walk season.
Eee d Edwd aexd
-
7/31/2019 COH AR 2006
34/54
| C i t y o f H o p e
-
7/31/2019 COH AR 2006
35/54
C i t y o f H o p e |
FiNANCiALS
Pe ifm
(For scal years beginning October 1 and ending September 30)
(dollar amounts in thousands)
Chge f Pe sevce 2006 % 2005 %
Medicare $ 231,246 25.4% $ 178,393 24.3%
Indemnity insurance 2,975 0.3% 8,266 1.1%
Managed care contracts 523,300 57.3% 422,939 57.4%
Subsidized care 155,332 17.0% 126,633 17.2%
Total $ 912,853 100.0% $ 736,231 100.0%
Pyme receved f Pe sevce 2006 % 2005 %
Medicare $ 56,503 17.1% $ 47,212 17.5%
Indemnity insurance 2,123 0.6% 3,296 1.2%
Managed care contracts 225,299 67.8% 199,242 73.7%
Medi-Cal and other 48,270 14.5% 20,463 7.6%
Total $ 332,195 100.0% $ 270,213 100.0%
Pe teed (ed dm) 2006 2005
New patient reerrals 6,419 6,148
Patients treated during year 17,695 16,894
Admissions 4,934 4,643
Patient days 49,330 43,745Clinic and inusion visits 109,603 102,605
Bone marrow transplants (BMT) 605* 460*
*includes BMT perormed at City o Hope Banner Good Samaritan
-
7/31/2019 COH AR 2006
36/54
| C i t y o f H o p e
Cy f Hpe d afe Cmed seme f Fc P
(For scal years beginning October 1 and ending September 30)
(dollar amounts in thousands)
assEts
Cue ae 2006 2005*
Cash and cash euivalents $ 49,473 $ 51,041
Investments 71,072 53,437
Patient accounts receivable, less allowances or uncollectibleaccounts o $3,377 in 2006 and $2,010 in 2005 64,415 52,971
Grants and other receivables 15,187 9,288
Donor restricted unconditional promises to give, net 10,588 11,867
Prepaid and other 28,291 15,322
Total current assets $ 239,026 $ 193,926
PROPERTY, PLANT AND EqUIPMENT, net o accumulateddepreciation o $273,123 in 2006 and $242,257 in 2005 $ 371,440 $ 366,246
ohe ae
Investments $ 9,133 $ 5,334
Board-designated investments 161,234 136,002
Bond trust unds 41,774 12,367
Escrow unds 1,699
Donor restricted assets 128,989 94,236
Other assets 11,870 10,532
Total other assets 353,000 260,170
TOTAL ASSETS $ 963,466 $ 820,342
*Certain reclassications were made to the 2005 nancial statements to conorm to the 2006 presentation.
-
7/31/2019 COH AR 2006
37/54
C i t y o f H o p e |
(For scal years beginning October 1 and ending September 30)
(dollar amounts in thousands)
liabilitiEs anD nEt assEts
Cue le 2006 2005*
Accounts payable and accrued liabilities $ 72,281 $ 98,545
Long-term debt, current portion and accrued interest 14,015 10,349
Total current liabilities 86,296 108,894
LONG-TERM DEBT, net o current portion and unamortizeddiscount o $2,131 and $2,259 as o September 30, 2006and 2005, respectively 241,144 191,613
ANNUITY AND SPLIT-INTEREST AGREEMENT OBLIGATIONS 19,670 19,037
Other 7,036 5,608
Total liabilities $ 354,146 $ 325,152
CoMMitMEnts anD ContinGEnCiEs
ne ae
Unrestricted $ 457,589 $ 382,940
Restricted 151,731 112,250
Total net assets 609,320 495,190
TOTAL LIABILITIES AND NET ASSETS $ 963,466 $ 820,342
*Certain reclassications were made to the 2005 nancial statements to conorm to the 2006 presentation.
-
7/31/2019 COH AR 2006
38/54
| C i t y o f H o p e
Cy f Hpe Cmed seme f acve
(For scal years beginning October 1 and ending September 30)
(dollar amounts in thousands)
reveue 2006 2005
Net patient service revenues $ 332,195 $270,213
Contributions and net special event revenues 124,867 85,645
Royalties and research grants 151,884 123,754
Other 32,330 23,995
Total revenues $ 641,276 $503,607
Expee
Program services $ 441,862 $370,107
Supporting services 83,780 82,437
Total expenses 525,642 452,544
Operating income 115,634 51,063
Change in net unrealized (loss) gain on investments (998) 6,755
Loss on interest rate swap agreement (506)
FEMA grant used or eligible construction projects 272
Changes in net assets 114,130 58,090
Net assets, beginning o year 495,190 437,100
Net assets, end o year $ 609,320 $495,190
-
7/31/2019 COH AR 2006
39/54
C i t y o f H o p e |
Cy f Hpe Cmed seme f Ch Fw
(For scal years beginning October 1 and ending September 30)
(dollar amounts in thousands)
Ch Fw fm opeg acve 2006 2005
Changes in net assets $114,130 $ 58,090
Adjustments to reconcile changes in net assets to net cashprovided by operating activities:
Depreciation and amortization 31,333 24,103
Unrealized (loss) gain on investments 998 (6,755)
Other changes in operating assets and liabilities (59,830) (17,321)
Total adjustments (27,499) 27
Net cash provided by operating activities $ 86,631 $ 58,117
Ch Fw fm iveg acve
Proceeds rom sales o property, plant and euipment $ 416 $ 786
Additions to property, plant and euipment (36,212) (56,707)
Change in investments (95,632) (21,560)
Net cash used in investing activities $(131,428) $ (77,481)
Ch Fw fm Fcg acve
Net cash provided by nancing activities $ 43,229 $ 33,066
Net increase in cash and cash euivalents (1,568) 13,702
Cash and cash euivalents, beginning o year 51,041 37,339
Cash and cash euivalents, end o year $ 49,473 $ 51,041
-
7/31/2019 COH AR 2006
40/54
| C i t y o f H o p e
and Tumor Immunology, and the departments o
Gene Regulation and Drug Discovery, Surgical
Research and Radiation Biology provide the
ramework or the institutes work.
national MEDiCal CEntEr
The National Medical Center is the place where
more than 138 physicians representing 25 board-
certied specialties help bring City o Hopes
research ull circle. Here, new and promisingtreatment options are made available to patients
long beore they become available in the community.
At any given time, City o Hope conducts more
than 300 clinical studies, involving 40 percent
o its eligible patients. The national average is less
than 5 percent.
Helord Clinical Research Hospital at
City o Hope, which opened in 2005, began a
new chapter in City o Hopes mission o bringing
cures to people battling cancer and other lie-
threatening illnesses. This state-o-the-art acility isthe culmination o decades o scientic, clinical
and undraising eorts. It embodies the organiza-
tions medical and technological expertise and
treatment approaches.
CEntEr For bioMEDiCinE & GEnEtiCs anD
tHE sYlVia r. & isaDor a. DEUtCH CEntEr For
aPPliED tECHnoloGY DEVEloPMEnt
Made possible by generous support rom the
National Oce Products Industry, the Center or
Biomedicine & Genetics (CBG) is licensedby the state and ederal government to produce
pharmaceutical-grade therapeutic compounds. This
provides a cost-eective way to expedite the delivery
o experimental biological therapies to patients.
City o Hope established the CBG to ensure that its
technological innovations are eciently translated
rom the research lab to the clinical setting, while
allowing scientic and clinical investigators the
PROgRAMSAND FACiLiTiES
CoMPrEHEnsiVE CanCEr CEntEr
A National Cancer Institute (NCI) Cancer Center
since 1981, City o Hope received the prestigious
comprehensive designation rom the NCI in 1998,
and it was renewed in 2004. This designation makes
City o Hope one o only a ew such centers in the
United States that combines all acets o cancer
research and care with the highest standards o
excellence. An additional component o the NCI
designation includes community outreach, educationand population-based research. City o Hopes
recently created Division o Population Sciences
addresses this by ocusing on understanding the
origins o cancer, as well as research to better
comprehend long-term outcomes o treatment.
City o Hope also sponsors community outreach
and education orums targeting both health-care
proessionals and the public. Through all o these
activities combined, NCI-designated cancer centers,
like City o Hope, play an important role in their
communities, infuencing standards o cancerprevention and treatment.
bECKMan rEsEarCH institUtE
With a sta o more than 545, including nearly
80 principal scientists, City o Hopes Beckman
Research Institute is one o the nations premier
centers or groundbreaking biomedical research.
City o Hope scientists undertake undamental
investigations in molecular genetics and cellular
biology; they study normal and abnormal biological
processes, including mutagenesis and DNA repair,cell dierentiation and early development, inter-
and intracellular signaling, RNA processing and
genome structure. These scientists have achieved
major advances in recombinant DNA technology,
monoclonal antibodies, gene therapy and radioim-
munotherapy. The divisions o Biology, Immunology,
Neurosciences, Molecular Medicine, Molecular
Biology, Virology and Cancer Immunotherapeutics
-
7/31/2019 COH AR 2006
41/54
C i t y o f H o p e |
reedom to test and rene the most promising new
therapeutics. As a National Gene Vector Laboratory,
the CBG is also responsible or the production o
plasmid DNA vectors or ederally unded gene
therapy research. In recognition o their generous
git, the rst foor o the CBG acility is named the
Sylvia R. & Isador A. Deutch Center or Applied
Technology Development.
GEnEral CliniCal rEsEarCH CEntErThe General Clinical Research Center (GCRC) at
City o Hope, a partnership with the University
o Southern Caliornia, is one o only 59 centers
nationwide unded by the National Center or
Research Resources o the National Institutes o
Health. The GCRC provides an optimal
setting or medical investigators to conduct sae,
controlled, state-o-the-art inpatient and
outpatient studies. GCRC resources include highly
trained research personnel, a core laboratory, a
bioinormatics system and a metabolic kitchen.The GCRC research sta includes nurses,
dietitians, biostatisticians, skilled technicians and
administrative personnel to help investigators by
acilitating the day-to-day research process and
assisting the research patients in a supportive
and ecient environment.
GraDUatE sCHool oF bioloGiCal sCiEnCEs
For 13 years, City o Hopes accredited Graduate
School o Biological Sciences has provided a
uniue training ground or tomorrows scientists. Itoers postgraduate training in molecular biology,
immunology, molecular medicine and neurosciences,
including academic classes and intensive laboratory
research. Working toward the completion o their
doctoral degrees, students have access to state-o-
the-art acilities and shared resources to acilitate
their research and are able to collaborate alongside
aculty who are experts in their elds.
CitY oF HoPE bannEr GooD saMaritan
bonE MarroW transPlantation (bMt)
ProGraM
In partnership with Banner Health System,
City o Hope has built a successul satellite BMT
program in Phoenix, serving area residents. This
joint program has been designated as a member o
the Southwest Oncology Group, one o the largest
o the National Cancer Institute-supported cancer
clinical trials cooperative groups in the UnitedStates. This provides patients with access to key
clinical trials and research protocols.
soUtHErn CaliFornia islEt CEll
rEsoUrCE CEntEr
Housed in the Leslie and Susan Gonda (Goldschmied)
Diabetes and Genetic Research Center, the Southern
Caliornia Islet Cell Resource (SC-ICR) center
is one o only seven islet cell resource (ICR) centers
unded by the National Institutes o Health.
City o Hope perormed the most islet transplantsin the U.S. in 2004 and 2005 and distributed the
largest number o islets to basic science programs
throughout the U.S. since 2004. During the most
recent unding period o the ICR program,
City o Hope was the only center unded in the
western U.S. In May 2004, City o Hope became the
rst islet transplant center without a whole organ
transplantation program to become a member o the
United Network o Organ Sharing. Additionally, in
2006, City o Hope was designated an islet cell
transplant center by the Juvenile Diabetes ResearchFoundation, making it one o only 14 institutions
in the U.S. to receive this distinction and the only
one in Southern Caliornia. The center also oers a
total-care diabetes and endocrinology program and
has helped millions o diabetics worldwide who
benet rom synthetic human insulin developed
through research conducted at City o Hope.
-
7/31/2019 COH AR 2006
42/54
0 | C i t y o f H o p e
RESEARCH AND CLiNiCALDiviSiONS, DEPARTMENTSAND PROgRAMS
CoMPrEHEnsiVE CanCEr CEntEr
rEsEarCH ProGraMs anD FaCilitiEs
Cancer Biology
Cancer Control and Population Sciences
Cancer Immunotherapeutics
Developmental Cancer Therapeutics
Hematologic Malignancies
bECKMan rEsEarCH institUtE
DiVisions
Biology
Cancer Immunotherapeutics and
Tumor Immunology
Immunology
Molecular Biology
Molecular Medicine
Neurosciences
Virology
national MEDiCal CEntEr DiVisions/
DEPartMEnts
Anesthesiology
Diagnostic Radiology
Nuclear Medicine
Hematology & Hematopoietic Cell TransplantationHematopoietic Stem Cell and
Leukemia Research
Inormation Sciences
Biomedical Inormatics
Biostatistics
Clinical Research Inormation Management
Medical Oncology & Therapeutics Research
Aging and Cancer Research Program
Clinical and Molecular Pharmacology
Medical Specialties
CardiologyDiabetes, Endocrinology & Metabolism
Gastroenterology
Inectious Diseases
Neurology
Psychology
Pulmonary and Critical Care Medicine
Supportive Care & Palliative Medicine
Pathology
Anatomic Pathology
Clinical Pathology
Transusion MedicinePediatrics
Population Sciences
Behavioral Oncology
Center or Cancer Survivorship
Center o Community Alliance or Research
& Education
Clinical Cancer Genetics
-
7/31/2019 COH AR 2006
43/54
C i t y o f H o p e |
Etiology
Nursing Research and Education
Outcomes Research/Intervention
Radiation Oncology
Clinical Radiation Oncology
Radiation Biology
Radiation Physics
Surgery
General and Oncologic Surgery
Neurosurgery
Orthopaedic Surgery
Plastic and Reconstructive Surgery
Surgical Research
Thoracic Surgery
Urology and Urologic Oncology
national MEDiCal CEntEr DisEasE-
sitE ProGraMs
Brain Tumor Program
Breast Cancer Program
Rita Cooper Finkel and J. William Finkel
Womens Health Center
Diabetes, Endocrinology & Metabolism
Gene Regulation and Drug Discovery
Islet Cell Transplantation Program
Gastrointestinal Cancer Program
General Clinical Research Center
Genitourinary/Prostate Cancer Program
Gynecologic Cancer ProgramLiver Cancer Program
Lymphoma SPORE
Musculoskeletal Tumor Program
Pediatric Cancer Program
Thoracic/Lung Cancer Program
-
7/31/2019 COH AR 2006
44/54
| C i t y o f H o p e
ADMiNiSTRATivE LEADERSHiPAND BOARD OF DiRECTORS
aDMinistration
Michael A. Friedman, M.D.
President and
Chie Executive Ofcer
Terry W. Blackwood, C.P.A.
Chie Financial Ofcer and
Treasurer
Debra F. Fields, J.D.
Chie Risk Ofcer
Kathleen L. Kane, J.D.
Executive Vice President,
Development and
External Aairs
Theodore G. Krontiris, M.D., Ph.D.
Executive Vice President,
Medical and Scientifc Aairs
Director, NCI-designated
Comprehensive Cancer Center
Alexandra M. Levine, M.D.
Chie Medical Ofcer
Virginia A. Opipare
Executive Vice President and
Chie Operating Ofcer
Arthur D. Riggs, Ph.D.
Director, Beckman Research
Institute
Chris A. Roederer
Chie Corporate Services Ofcer
Robert W. Stone, J.D.
General Counsel and Secretary
boarD oF DirECtors
Chair
Philip L. Engel
Immediate Past Chair
Jack R. Suzar*
Vice Chairs
Sheri J. Biller
Terry R. Peets, Chair-elect
Chairs Emeritus
Meyer E. Hersch*
Gil N. Schwartzberg,* J.D.
Richard S. Ziman*
General Vice Chair
Ben Horowitz
Members
Donald Bailey Sr.
Robert A. Cook
L. Dale Crandall
Israel J. Freeman
Robbin L. Itkin
Stephen B. Kass
Jerey G. Katz
Jacueline B. Koseco, Ph.D.
Thomas A. Madden
Robert G. Miller
Gail K. Naughton, Ph.D.
John R. Ohanesian
Norman C. Payson, M.D.
Claire L. RothmanJoseph P. Sanord
Laura A. Schulte
Ernie C. So
Stephan E. Tow
Honorary Directors
Michael B. Kaplan,* J.D.
Sidney L. Kline*
Mark B. Levey*
MEDiCal CEntEr boarD
oF DirECtors
Chair
Jacueline B. Koseco, Ph.D.
Vice Chair
Ernie C. So
Members
Donald S. David, M.D.
Mordecai N. Dunst, M.D.Israel J. Freeman
Donald W. Homan
Ben Horowitz
Robbin L. Itkin
Robert J. Morgan, M.D.
Richard B. Myers*
Claire L. Rothman
Iris Rothstein*
Andrew Spiegl*
Esther A. Torrez*
bECKMan rEsEarCH
institUtE boarD oF
DirECtors
Chair
Stephen B. Kass
Members
Gary E. Freedman
Ben Horowitz
Jacueline B. Koseco, Ph.D.
Harry Levitt
Elliot Rosman
John J. Rossi, Ph.D.
Iris Rothstein*
Ernie C. So
*Also on the Board o Regents
-
7/31/2019 COH AR 2006
45/54
C i t y o f H o p e |
CHairs oF tHE boarD
Barnett Cohen (1913-1920)
Benjamin Forer (1920-1922)
Dr. Henry Silverberg (1922-1925)
J.A. Rosenkranz (1925-1926,
1933-1936, 1939-1941)
Dr. Nahum Kavinoky (1926-1927)
Chaim Shapiro (1927-1929)
Dr. Moses I. Devorkin
(1929-1931)
Lester W. Roth (1931-1933)
Mark Carter (1936-1939)
Pinches Karl (1941-1944)
Ben Solnit (1944-1946)
Louis Tabak (1946-1949,
1957-1961)
Victor M. Carter (1949-1957)
Seymour Gra(1961-1964)
Emanuel H. Fineman (1964-1971)
Percy Solotoy (1971-1975)
Meyer E. Hersch (1975-1983)
Abraham S. Bolsky (1983-1989)
Richard S. Ziman (1989-1995)
Gil N. Schwartzberg, J.D.
(1995-1999)
Jack R. Suzar (1999-2004)
Philip L. Engel (2004-present)
boarD oF rEGEnts
Chair
Jack R. Suzar
Chairs Emeritus
Meyer E. Hersch
Gil N. Schwartzberg, J.D.
Richard S. Ziman
Members
Rhoda K. EhrlichBonnie L. Fein
John T. Frankenheimer, J.D.
Leon Frieden
Richard D. Gibbs
Robert N. Goodman
Michael Greenberg
Zachary I. Horowitz
Louise Horvitz, M.S.W., Psy.D.
Bryan Isaacs
Michael B. Kaplan, J.D.
Sidney L. Kline
Laurie Konheim
Mark B. Levey
Rhoda Makadon
David Z. Marmel
Jack L. Meyers
David Morse
Richard B. Myers
Mark Oli
Ricky Paskow
Iris Rothstein
Nina Madden Sabban
Clarence T. Schmitz
Judge Bernard Selber
Bernard J. Siegel
Andrew Spiegl
Adrienne Ehrlich Stern
Bobbie M. Stern
Esther A. Torrez
Dan E. Young
-
7/31/2019 COH AR 2006
46/54
| C i t y o f H o p e
FACuLTy LEADERSHiP
CoMPrEHEnsiVE CanCEr CEntEr
THEODORE G. KRONTIRIS, M.D., Ph.D.
Director
Executive Vice President, Medical and Scientifc
Aairs
RICHARD JOVE, Ph.D.
Deputy Director
MICHAEL BENEDICT, Pharm.D.
Associate Director or Administration
SMITA BHATIA, M.D., M.P.H.
Associate Director or Population Research
ROBERT A. FIGLIN, M.D.Associate Director or Clinical Research
JOYCE C. NILAND, Ph.D.
Associate Director or Inormation Sciences
JOHN J. ROSSI, Ph.D.
Associate Director or Laboratory Research
YUN YEN, M.D., Ph.D.
Associate Director or Translational Research
Cce bgy Pgm
JOHN J. ROSSI, Ph.D.
Co-leader
GERD P. PFEIFER, Ph.D.
Co-leader
Cce C d Ppu scece
Pgm
SMITA BHATIA, M.D., M.P.H.
Co-leaderMARCIA GRANT, R.N, D.N.Sc.
Co-leader
Cce immuhepeuc Pgm
ANDREW A. RAUBITSCHEK, M.D.
Co-leader
MICHAEL C. JENSEN, M.D.
Co-leader
Devepme Cce thepeuc Pgm
RICHARD JOVE, Ph.D.
Co-leader
YUN YEN, M.D., Ph.D.
Co-leader
Hemgc Mgce Pgm
STEPHEN J. FORMAN, M.D.
Co-leader
RAVI BHATIA, M.D.
Co-leader
bECKMan rEsEarCH institUtE
ARTHUR D. RIGGS, Ph.D.
Director
SUSAN E. KANE, Ph.D.
Associate Director
Dv f bgy
GERD P. PFEIFER, Ph.D.
Chair
-
7/31/2019 COH AR 2006
47/54
C i t y o f H o p e |
Dv f Cce immuhepeuc d
tum immugy
ANDREW A. RAUBITSCHEK, M.D.
Chair
Director, Department o Radioimmunotherapy
MICHAEL C. JENSEN, M.D.
Associate Chair
STEPHEN J. FORMAN, M.D.
Clinical DirectorDv f immugy
JOHN E. SHIVELY, Ph.D.
Chair
Dv f Mecu bgy
JOHN J. ROSSI, Ph.D.
Chair
Lidow Family Research Chair
Dv f Mecu Medce
RICHARD JOVE, Ph.D.
Chair
STEVE S. SOMMER, Ph.D.
Director, Department o Molecular Genetics
Director, Department o Molecular Diagnosis
Dv f neucece
MICHAEL E. BARISH, Ph.D.
Chair
Dv f Vgy
JOHN A. ZAIA, M.D.
Chair
national MEDiCal CEntEr DiVisions/
DEPartMEnts/ProGraMs
Dv f aehegy
MICHAEL LEW, M.D.
Chair
Dv f Dgc rdgy
J. MARTIN HOGAN, M.D.
Chair
Depme f nuce Medce
DAVE YAMAUCHI, M.D.
Director
Dv f Hemgy & Hempec Ce
tp
STEPHEN J. FORMAN, M.D.Chair
Francis and Kathleen McNamara Distinguished
Chair in Hematology and Hematopoietic
Cell Transplantation
AUAYPORN NADEMANEE, M.D.
Associate Clinical Director
MARGARET ODONNELL, M.D.
Associate Clinical Director
DAVID S. SNYDER, M.D.
Associate Director
acue Myegeu leukem Pgm
ANTHONY STEIN, M.D.
Director
Cc reech Pgm
EILEEN SMITH, M.D.
Associate Director
Hempec Ce thepe ly
DAVID DIGIUSTO, Ph.D.
Director
Depme f Hempec sem Ce d
leukem reech
RAVI BHATIA, M.D.
Director
Hcmpy ly
DAVID SENITZER, Ph.D.
Director
-
7/31/2019 COH AR 2006
48/54
| C i t y o f H o p e
immugy Ceve sude ly
MICHAEL KALOS, Ph.D.
Director
lg-em Fw-up Pgm
SMITA BHATIA, M.D., M.P.H.
Director
Medc Educ & tg Pgm
AMRITA KRISHNAN, M.D.
DirectorMched Ueed D Hempec Ce
tp Pgm
AUAYPORN NADEMANEE, M.D.
Director
Director, Lymphoma Program
new Dug Devepme
MARK KIRSCHBAUM, M.D.
Director
Dv f ifm scece/bc
JOYCE C. NILAND, Ph.D.Chair
Edward and Estelle Alexander Chair in
Inormation Sciences
Depme f bmedc ifmc
DOUGLAS C. STAHL, Ph.D.
Director
Depme f bc
JEFFREY LONGMATE, Ph.D.
Director
Depme f Cc reech ifm
Mgeme
DINA JOHNSON
Director
Dv f Medc ocgy & thepeuc
reech
ROBERT A. FIGLIN, M.D.
Chair
Arthur and Rosalie Kaplan Proessor o Medical
Oncology
agg d Cce reech Pgm
ARTI HURRIA, M.D.
Director
Depme f Cc d Mecu
Phmcgy
YUN YEN, M.D., Ph.D.
Director
Dv f Medc spec
K. VENKATARAMAN, M.D.
Chair
Depme f Cdgy
K. VENKATARAMAN, M.D.
Director
Depme f Dee, Edcgy &
Mem
FOUAD R. KANDEEL, M.D., Ph.D.
Director
Depme f Geegy
DONALD DAVID, M.D.
Director
President, Medical Sta
Depme f ifecu Dee
JAMES I. ITO, M.D.Director
Depme f neugy
HARRY O. OPENSHAW, M.D.
Director
Depme f Pychgy
MARTIN PEREZ, Ph.D.
Co-director
-
7/31/2019 COH AR 2006
49/54
C i t y o f H o p e |
ANDREA THORNTON, Ph.D.
Co-director
Depme f Pumy d Cc Ce
Medce
DAVID A. HORAK, M.D.
Director
Depme f suppve Ce &
Pve Medce
NEAL SLATKIN, M.D.Director
Dv f Phgy
LAWRENCE M. WEISS, M.D.
Chair
Depme f amc Phgy/Cygy
SHARON P. WILCZYNSKI, M.D., Ph.D.
Director
Depme f Cc Phgy
KAREN L. CHANG, M.D.
Director
Depme f Cygeec
MARILYN SLOVAK, Ph.D.
Director
Depme f tfu Medce
JOY FRIDEY, M.D.
Director
Dv f Pedc
JUDITH K. SATO, M.D.
Acting Chair
Director, Department o Pediatric Hematology/
Oncology
JOSEPH ROSENTHAL, M.D.
Director, Department o Pediatric Hematopoietic
Cell Transplantation
Dv f Ppu scece
SMITA BHATIA, M.D., M.P.H.
Chair
Cee f Cce suvvhp
SMITA BHATIA, M.D., M.P.H.
Medical Director
WENDY LANDIER, R.N., M.S.N.
Clinical Director
Cee f Cmmuy ace f reech &Educ
KIMLIN TAM ASHING-GIWA, Ph.D.
Director
Depme f Cc Cce Geec
JEFFREY N. WEITZEL, M.D.
Director
Depme f nug reech d Educ
MARCIA GRANT, R.N, D.N.Sc.
Director
Depme f oucme reech/
ieve
SMITA BHATIA, M.D., M.P.H.
Director
Dv f rd ocgy
JEFFREY Y.C. WONG, M.D.
Chair
Cc rd ocgy
JEFFREY Y.C. WONG, M.D.
Director
Depme f rd bgy
BINGHUI SHEN, Ph.D.
Director
Depme f rd Phyc
TIMOTHY E. SCHULTHEISS, Ph.D.
Director
Proessor, Division o Radiation Oncology
-
7/31/2019 COH AR 2006
50/54
| C i t y o f H o p e
Dv f sugey
I. BENJAMIN PAZ, M.D.
Co-chair
TIMOTHY G. WILSON, M.D.
Co-chair
Depme f Gee ocgc sugey
I. BENJAMIN PAZ, M.D.
Director
Depme f neuugeyBENHAM BADIE, M.D., F.A.C.S.
Director
Depme f ohpedc sugey
J. DOMINIC FEMINO, M.D.
Director
Depme f Pc d recucve
sugey
JAMES S. ANDERSEN, M.D.
Director
Depme f sugc reech
SHIUAN CHEN, M.D.
Director
Depme f thcc sugey
KEMP H. KERNSTINE, M.D., Ph.D.
Director
Depme f Ugy d Ugc ocgy
TIMOTHY G. WILSON, M.D.
Director
Pauline and Martin Collins Family Chair
in Urology
DisEasE-sitE ProGraMs
b tum Pgm
BENHAM BADIE, M.D.
Director
be Cce Pgm
I. BENJAMIN PAZ, M.D.
Co-director, Breast Cancer Program
Director, Rita Cooper Finkel and J. William Finkel
Womens Health CenterGEORGE SOMLO, M.D.
Co-director, Breast Cancer Program
Director, Breast Oncology
Associate Director, High-dose Chemotherapy,
Division o Medical Oncology & Therapeutics
Research
Director, Multiple Myeloma Program
Depme f Dee, Edcgy & Mem
FOUAD R. KANDEEL, M.D., Ph.D.
DirectorDepme f Gee regu d
Dug Dcvey
BARRY M. FORMAN, M.D., Ph.D.
Ruth B. and Robert K. Lanman Endowed
Chair in Gene Regulation and Drug
Discovery Research
ie Ce tp Pgm
FOUAD R. KANDEEL, M.D., Ph.D.
Director
Ge Cce PgmSTEPHEN SHIBATA, M.D.
Director
JOSHUA ELLENHORN, M.D.
Associate Director
-
7/31/2019 COH AR 2006
51/54
C i t y o f H o p e |
Gee Cc reech Cee
JOHN A. ZAIA, M.D.
Director
Geuy/Pe Cce Pgm
TIMOTHY G. WILSON, M.D.
Director
JEFFREY Y.C. WONG, M.D.
Associate Director
Gyecgc Cce PgmMARK WAKABAYASHI, M.D., M.P.H.
Director
lve Cce Pgm
LAWRENCE D. WAGMAN, M.D.
Director
lymphm sPorE
STEPHEN J. FORMAN, M.D.
Principal Investigator
ANDREW A. RAUBITSCHEK, M.D.
Co-principal Investigator
Pedc/Mucukee Cce Pgm
JUDITH A. SATO, M.D.
Co-director
J. DOMINIC FEMINO, M.D.
Co-director
thcc/lug Cce Pgm
KEMP H. KERNSTINE, M.D., Ph.D.
Director
otHEr institUtional rEsoUrCEs
am reuce Cee
RICHARD ERMEL, D.V.M., Ph.D.
Director
Cee f apped techgy Devepme
LARRY A. COUTURE, Ph.D.
Senior Vice President
Cee f bmedce & Geec
DAVID HSU, Ph.D.
Director
techgy lceg
BRIAN R. CLARK, Ph.D.
DirectorCee f Gdue & Pfe sude
SUSAN E. KANE, Ph.D.
Senior Vice President, Academics
STEVEN NOVAK, Ph.D.
Director, Academics
Gdue sch f bgc scece
JOHN J. ROSSI, Ph.D.
Dean
Depme f Cug Medc Educ
ROBERT J. MORGAN JR., M.D.
Director
-
7/31/2019 COH AR 2006
52/54
0 | C i t y o f H o p e
LOCATiONS
Cy f Hpe d
beckm reech iue
1500 East Duarte Road
Duarte, Cali. 91010-3000
800-423-7119
www.cityohope.org
Cy f Hpe
Devepme Hedque
1055 Wilshire BoulevardLos Angeles, Cali. 90017
800-544-3541
Cy f Hpe
be Gd sm
be Mw tp
Pgm
1111 East McDowell Road,
Suite 12b
Phoenix, Ariz. 85006
reg Devepme ofce
SOuTHEAST
Fort Lauderdale, Fla.
800-584-6709
MiDWEST
Chicago
800-779-5893
NORTHEAST
Philadelphia
800-344-8169
SOuTHWEST
San Diego
888-805-8911
Phoenix
800-732-7309
Palm Desert, Cali.
800-732-7121
Orange County, Cali.
800-235-0579
NORTHWEST
San Francisco
800-732-7140
Seattle
800-934-9196
Prodced b: Ct of Hope Commncatons Department nder the drecton of Senor vce Presdent Brenda Maceo
Project Manaer: Tana M. Marn
Wrters: gre voel, Stee Krk, Tana Marn, Alca D Rado
Art Drecton and Desn:The Jefferes Assocaton
Prncpal Photoraph: Phl Channn
Prnted b: Colorgraphcs Los Aneles
-
7/31/2019 COH AR 2006
53/54
-
7/31/2019 COH AR 2006
54/54
1500 East Duarte Road
Duarte, Calif. 91010-3000
top related